Biopharmconsortium Blog

Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting.

• Blog Archive

  • January 2012 (2)
  • December 2011 (2)
  • November 2011 (2)
  • October 2011 (2)
  • September 2011 (2)
  • August 2011 (3)
  • July 2011 (3)
  • June 2011 (2)
  • May 2011 (3)
  • April 2011 (1)
  • March 2011 (3)
  • February 2011 (2)
  • January 2011 (2)
  • December 2010 (5)
  • November 2010 (6)
  • October 2010 (3)
  • September 2010 (3)
  • August 2010 (5)
  • July 2010 (3)
  • June 2010 (2)
  • May 2010 (3)
  • April 2010 (3)
  • March 2010 (4)
  • February 2010 (2)
  • January 2010 (2)
  • December 2009 (2)
  • November 2009 (2)
  • October 2009 (1)
  • September 2009 (3)
  • August 2009 (2)
  • July 2009 (4)

• Meta

  • Register
  • Log in
  • Entries RSS
  • Comments RSS
  • WordPress.org

• Categories

  • About Our Blog (6)
  • Animal Models (12)
  • Anti-Aging (5)
  • Biomarkers (11)
  • Cancer (33)
  • Cardiovascular disease (3)
  • Chemistry (8)
  • Drug development (48)
  • Drug discovery (44)
  • Epigenetics (3)
  • Haberman Associates (18)
  • Immunology (3)
  • Infectious disease (3)
  • Metabolic diseases (19)
  • Metabolism (3)
  • Monoclonal Antibodies (4)
  • Neurodegenerative diseases (5)
  • Personalized medicine (21)
  • Psychiatric diseases (2)
  • RNAi (6)
  • Stem Cells (7)
  • Strategy and Consulting (52)
  • Synthetic biology (7)
  • Translational medicine (20)
  • Uncategorized (1)

• Contact information

  Allan B. Haberman, Ph.D.
  Wayland, MA United States

  Principal, Haberman Associates. Science and technology strategy consulting for life science companies.

  allanhab@biopharmconsortium.com

  www.biopharmconsortium.com

  Follow us on Twitter: